INTRODUCTION {#sec0005}
============

Subthalamic nucleus deep brain stimulation (STN-DBS) is an effective adjunctive therapy for advanced stage Parkinson's disease (PD) that improves motor symptoms and quality of life while also reducing medication requirements and complications associated with medical therapy \[[@ref001]\]. A prospective, randomized,single blind, pilot clinical trial demonstrated initial safety and tolerability of STN-DBS in early stage PD \[[@ref002]\], and the FDA has approved a pivotal, phase III, multicenter, safety and efficacy trial evaluating DBS in early PD. In the pilot trial, early PD subjects randomized to receive DBS plus optimal drug therapy (DBS+ODT) required less medications than the ODT group at each follow-up visit \[[@ref002]\], which is consistent with the established medication reduction associated with STN-DBS in advanced stage PD. Medication costs are one of the most important economic drivers of healthcare expenditures, and increasing cost negatively impacts patient access to and compliance with prescribed therapies. Here, we report a medication cost analysis from the only prospective study of DBS in early stage PD and offer a projection of medication cost from early PD until the time that a typical patient would be treated with DBS \[[@ref001]\].

MATERIALS AND METHODS {#sec0010}
=====================

Investigators at Vanderbilt University conducted a prospective, randomized, single-blind clinical trial testing STN-DBS in early stage PD (NCT\#00282152) from 2006--2012 that was approved by the FDA (IDE\#G050016) and Vanderbilt University IRB (IRB\#040797). Study design, enrollment experience, baseline characteristics, and outcomes are published elsewhere \[[@ref002]\]. Briefly, the pilot enrolled thirty idiopathic PD subjects, age 50--75 years (60.2±6.6), Hoehn & Yahr Stage II off medication, with a medication duration of 6 months to 4 years (2.1±1.5) without dyskinesias or other motor fluctuations who provided written informed consent. After baseline evaluations, subjects were randomized to receive ODT or DBS+ODT. Subjects' PD medication regimens were recorded at each visit (baseline, 6, 12, 18, and 24 months) and converted to levodopa equivalents (LEDD) \[[@ref006]\]. This analysis includes all subjects who completed at least one follow-up visit (*n* = 29).

To minimize bias, the subject's treating neurologist (not the principal investigator) was responsible for medication adjustments and could use any available therapy to manage PD symptoms. The following PD medications and classes were identified in this cohort: Levodopa --carbidopa/levodopa; Levodopa+COMT Inhibitor --carbidopa/levodopa/entacapone; Dopa-mine Agonists --pramipexole, rotigotine, ropinirole; MAO-B Inhibitors --selegeline, rasagiline; Antiviral --amantadine \[[@ref007]\]. Medication strengths, doses, and frequencies were collected at each visit and verified by medical record chart review.

Daily medication costs were calculated using prices listed in the Drug Topics Red Book (2010 edition). The lowest cost available was selected for medications with multiple pill quantities listed. Generic costs were used if a generic medication was available at the time of study visit. Medication data collected at each visit in the pilot were used to calculate the average daily cost for PD medications. Cumulative annual costs during the pilot were calculated by adding annual costs from 12 months and 24 months.

For cost projections, a 10% annual increase in medication cost was projected for ODT and DBS+ODT groups due to disease progression and greater complexity of PD medications \[[@ref008]\]. Additionally, a reduced annual increase in medication cost (5%) was also projected for the DBS+ODT group because subjects receiving STN-DBS at any stage of illness often utilize significantly less medication \[[@ref001]\].

Baseline daily medication costs were compared using a Mann-Whitney U test. To account for the small sample size, a likelihood ratio test was used to compare polypharmacy status between the two groups.

RESULTS {#sec0015}
=======

Average baseline daily costs were similar for the ODT and DBS+ODT groups, \$13.81 (±\$6.98) and \$13.39 (±\$5.98), respectively (*p* = 0.70; [Fig. 1A](#jpd-6-jpd150712-g001){ref-type="fig"}). Daily cost increased for the ODT group at each six-month visit, reaching a 72% increase from baseline by 24 months (\$23.82±\$27.95). Conversely, after STN-DBS surgery, the DBS+ODT group medication cost was less than baseline values at each follow-up visit, with a 16% decrease from baseline at 24 months (\$11.31±\$7.80). Annual medication costs at 24 months were \$8,694 for the ODT group and \$4,128 for the DBS+ODT group. The average cumulative medication costs from the pilot were \$14,662 and \$7,512 for the ODT and DBS+ODT groups, respectively ([Fig. 1A](#jpd-6-jpd150712-g001){ref-type="fig"}). This between-group difference during the two-year pilot translates into a total cumulative medication cost savings of \$7,150 for the DBS+ODT group.

[Figure 1B](#jpd-6-jpd150712-g001){ref-type="fig"} presents annual and cumulative medication costs projected from the conclusion of the pilot trial in early stage PD (average disease duration = 2.1 years \[[@ref002]\]) through advanced stage disease. A 10% annual increase in medication cost was assigned to both groups due to disease progression and greater complexity of PD medications \[[@ref008]\]. Additionally, a reduced annual increase in medication cost (5%) isalso projected for the DBS+ODT group based on the established medication reduction associated withSTN-DBS in advanced PD stages \[[@ref001]\]. Based on 10% increase estimates, annual medication costs will reach \$18,637 for the ODT group and \$8,849 for the DBS+ODT group in advanced PD (12 years disease duration), and DBS+ODT is projected to reduce the total cumulative medication costs by \$64,590 over 10 years. Furthermore, medication cost savings projected using a reduced 5% annual medication cost increase for the DBS+ODT group would reach \$75,129 after 10 years.

Because medication costs are directly influenced by the classes of medications prescribed, we analyzed medication classes contributing to total LEDD. Total LEDD for the ODT group was increased from baseline at each follow-up visit, with a 50% increase by 24 months ([Fig. 2A](#jpd-6-jpd150712-g002){ref-type="fig"}, \[[@ref002]\]). This increase in total LEDD for the ODT group is largely driven by increased utilization of the levodopa+COMT inhibitor medication class ([Fig. 2B](#jpd-6-jpd150712-g002){ref-type="fig"}). Total LEDD decreased in the DBS+ODT group at each visit from baseline through 18 months and then rose to a 16% increase by 24 months ([Fig. 2A](#jpd-6-jpd150712-g002){ref-type="fig"}). When medication need did increase in the DBS+ODT group, levodopa was most commonly utilized ([Fig. 2B](#jpd-6-jpd150712-g002){ref-type="fig"}). Furthermore, dopamine agonists for the DBS+ODT group were reduced from baseline at each visit, reaching a 25% reduction by 24 months. Finally, the proportion of ODT subjects on polypharmacy increased from 43% to 71% (baseline to 24 months), while there was no increase in the proportion of DBS+ODT subjects on polypharmacy (33%) at the end of the pilot trial ([Fig. 2C](#jpd-6-jpd150712-g002){ref-type="fig"}). ODT subjects were 5 times more likely to require polypharmacy at 24 months compared to DBS+ODT subjects (*p* \<  0.05; OR = 5.0; 95% CI 1.03--24.28).

DISCUSSION {#sec0020}
==========

This study reports PD medication cost savings of \$7,150 over two years with STN-DBS in early stage PD. It is well established that STN-DBS significantly reduces medication utilization in advanced PD. Therefore, projections were calculated for medication cost over the time from early PD until a typical advanced stage patient would be offered DBS. Using conservative assumptions, substantial cumulative medication cost savings are predicted to result when STN-DBS is applied in early PD (\$64,590 over 10 years).

The costs associated with DBS (such as the device, surgical procedures, and battery replacements) make it a significantly more expensive treatment option than standard medical therapy; however, this additional cost is justified for advanced PD patients by the superior quality of life, improved motor function, and decreased complications of medical therapy that DBS provides \[[@ref001]\]. Although the savings projected here do not outweigh the costs associated with STN-DBS, the predicted long-term medication reduction and associated decrease in medication costs represent a significant offset. PD progression requires higher doses of medications used in more complex combinations, which increases total costs. Indeed, the medication cost savings observed for the DBS+ODT group in this study ([Fig. 1A](#jpd-6-jpd150712-g001){ref-type="fig"}) is attributed to not only reduced total medication requirement ([Fig. 2A-B](#jpd-6-jpd150712-g002){ref-type="fig"}) but also the ability to maintain a simpler medication regimen compared to the ODT group ([Fig. 2C](#jpd-6-jpd150712-g002){ref-type="fig"}). Additionally, because STN-DBS in advanced PD reduces medication utilization, the associated complications and side effects are also likely reduced \[[@ref001]\]. Application of DBS in early stage PD, prior to the onset of these medication associated complications and side effects, has the potential to suppress their development by simply imparting less medication need over the course of the disease.

There are a number of limitations that should be considered for this analysis in addition to surgical risks associated with this line of research. Medications were not adjusted using a standardized treatment algorithm, which is a limitation of this study. To reduce bias however, medications in the pilot were managed by the subject's treating neurologist (not the principal investigator) who could use any available therapies to manage PD symptoms. The pilot trial was an open-label, single-blind study, and therefore placebo or lessebo effects may have influenced subjects' medication utilization \[[@ref010]\]. The study is limited by its small sample size, and this analysis only reflects the PD medications that were available during the study period (2006--2012). While generic versions are now available for some of the medications utilized during this trial, it is important to note that the landscape of PD medications continues to evolve. New pharmacological options are associated with significant cost, and therefore, the projections presented here likely underestimate future savings. There are surgical risks associated with DBS therapy when it is applied in early, mid, or late stage disease. Additional study is needed to determine if these risks are outweighed by the benefit of the therapy if applied in early stage disease. Potential research participants are entitled to make informed decisions regarding their clinical care and their participation in studies of DBS in early stage PD \[[@ref011]\]. Without a biomarker for Parkinson's disease, there is a chance that early application of DBS will include patients who are later determined to have a condition other than idiopathic PD. The Movement Disorders Society has recently published new guidelines that could be helpful in reducing this occurrence \[[@ref012]\], and it is important to note that there were no subjects in the pilot trial who have had an alternate diagnosis after 5 years of follow-up (*n* = 29).

A conservative approach was taken for this analysis and projection to avoid exaggerating cost savings. In 2004, we reported annual medication costs for advanced PD subjects prior to receiving STN-DBS to be \$7,172 \[[@ref008]\], and that report offered estimates of the impact of inflation on medication costs over time. Advanced PD patients without STN-DBS from that 2004 study would have annual medication costs reach \$20,462 in 2015 prices (using a 10% annual medication cost inflation rate) \[[@ref008]\], which closely aligns with our current projection of annual cost for advanced stage PD treated with ODT (\$18,637; [Fig. 1B](#jpd-6-jpd150712-g001){ref-type="fig"}). Additionally, two projections of annual increase in medication cost for the DBS+ODT group are presented. A 10% annual medication increase rate is presented for both ODT and DBS+ODT groups (10 year medication cost savings projection = \$64,590), and a reduced annual medication increase of 5% is also projected to reflect the well-established ability of STN-DBS to decrease PD medication burden and cost (10 year medication cost savings projection = \$75,129). Moreover, inflation was not factored into the analysis presented here. If more aggressive assumptions are applied, such as a 10% annual increase due to medication cost inflation, the projected medication savings resulting from STN-DBS in early stage PD would reach \$81,927.

The long-term PD medication cost savings of STN-DBS in early stage PD are secondary to the need for improved patient outcomes such as better motor function and quality of life and suppression of the complications of medical therapy. DBS+ODT is proven to offer superior outcomes to ODT in all PD stages tested thus far \[[@ref001]\]. A multicenter, randomized controlled trial of STN-DBS in mid-stage PD demonstrated significant medication reduction with DBS+ODT after two years which is predicted to result in significant medication cost savings \[[@ref009]\]. While the cost of DBS therapy is significant, STN-DBS applied in early stage PD may impart a substantial reduction in medication utilization and cost over many more years than when DBS is applied in current standard of care ([Fig. 1](#jpd-6-jpd150712-g001){ref-type="fig"}). Even though these savings do not exceed the cost of DBS therapy, they do represent a substantial offset when considered over the course of the disease. Additional investigation into the safety and efficacy of DBS in early stage PD is indicated, and the FDA has approved a pivotal, multicenter, phase III, clinical trial evaluating STN-DBS in early stage PD.
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![Medication cost and projections from the DBS in early PD pilot trial. (A) Average daily medication costs at each visit (lines, left y-axis). Average total cumulative annual medication costs from baseline at 12 months and 24 months (bars, right y-axis). (B) Annual (left y-axis) and cumulative (right y-axis) medication costs observed for ODT and DBS+ODT groups based on the pilot (cumulative medication costs are shown from the DBS in early PD pilot trial baseline). Annual medication increases of 10% were projected for ODT and DBS+ODT groups, and an increase of 5% is also projected for the DBS+ODT group.](jpd-6-jpd150712-g001){#jpd-6-jpd150712-g001}

![Medication class contributions. (A) Average relative contributions of medication classes to total LEDD (mg) over the two-year study period. (B) Average change from baseline for LEDD (mg) by medication class. (C) Proportion of subjects prescribed more than one type of PD medication (polypharmacy) at baseline and each six-month visit. n.s. = not significant, \*=*p* \<  0.05.](jpd-6-jpd150712-g002){#jpd-6-jpd150712-g002}
